Clinical Trial Update: Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy [Phase 2]

View source ↗

Summary

The Phase 2 extension study of ACE-031 for Duchenne muscular dystrophy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• ACE-031

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: TERMINATED